GlobeNewswire

Extra bolagsstämma i Oasmia Pharmaceutical AB den 6 november 2019

Dela

Oasmia Pharmaceutical AB (publ) höll under onsdagen den 6 november 2019 en extra bolagsstämma. Stämman beslutade i enlighet med styrelsens förslag att styrelsen får i bemyndigande att intill nästa årsstämma vid ett eller flera tillfällen besluta om nyemission av aktier, inom bolagsordningens gränser, med företrädesrätt för befintliga aktieägare att betalas kontant, genom apport och/eller genom kvittning.

Syftet med bemyndigandet är att likviden från företrädesemissionen huvudsakligen ska användas för att finansiera och accelerera kommersialiseringen av Apealea samt tillvarata nya affärsmöjligheter baserade på Bolagets unika XR17-plattform. Därutöver avser Oasmia att skapa en stabil finansiell position för Bolaget som möjliggör en expansion inom nya områden samt ett stabilt flöde av nya projekt.

Utgivande av nya aktier med stöd av bemyndigandet skall genomföras på sedvanliga villkor under rådande marknadsförhållanden. Styrelsen äger rätt att besluta om nyemissioner om upp till ett sammanlagt belopp om cirka 400 miljoner kronor med stöd av bemyndigandet.

Styrelsen, eller den som styrelsen utser, skall ges rätt att vidta de smärre justeringar av ovanstående beslut som kan visa sig erforderliga i samband med registrering vid Bolagsverket.

Det antecknas att emissionsbemyndigande som beslutades på årsstämman den 26 september 2019 gäller vid sidan av ovanstående emissionsbemyndigande, oavsett om ovanstående bemyndigande kommer till tillämpning eller inte.

För mer information:
Urban Ekelund, IR-chef Oasmia
E-post: IR@oasmia.com

Om Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB utvecklar, tillverkar, marknadsför och säljer en ny generation av läkemedel inom human- och veterinär onkologi. Produktutvecklingen syftar till att framställa nya formuleringar innehållande nanopartiklar av väletablerade cytostatika som i jämförelse med befintliga alternativ har förbättrande egenskaper, förbättrad biverkningsprofil samt bredare användningsområden. Produktutvecklingen bygger på egen forskning inom nanoteknik och egna patent. Bolagets aktie är noterad på Nasdaq Stockholm (OASM) och Frankfurt Stock Exchange (OMAX.GR).

Bilaga

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met16.11.2019 10:10:00 CETPress release

UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release. The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada. The preliminary data recently released from the pha

AMG Advanced Metallurgical Group N.V. Completes Acquisition of International Specialty Alloys15.11.2019 23:30:00 CETPress release

Amsterdam, 15 November 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") has finalized the acquisition of the assets of International Specialty Alloys ("ISA"), a leading U.S. producer of titanium master alloys and other binary alloys for the aerospace market, from Kennametal, Inc. The acquisition was previously announced on October 9, 2019 and closed and became effective today. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & chemicals end markets. AMG Critical Materials produces aluminum master alloys and powders, ferrovanadium, natural graphite, chromium metal, antimony, lithium, tantalum, niobium and silicon metal. AMG Technologies produces titanium aluminides and titanium alloys for the aerospace market; designs,

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease15.11.2019 21:06:00 CETPress release

Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs 6.87) in a 52-week study2 Approximately 100,000 people in the United States, most of whom are of African descent, have sickle cell disease3 Approval comes approximately two months ahead of FDA’s priority review action date, allowing Adakveo to be available to patients more quickly Basel, November 15, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo ® (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.4 Adakveo represents the first FDA-approved medicine in sickle cell disease that binds to P-selectin –a cell adhesion protein that plays a central r

SFL - Invitation to Presentation of Q3 2019 Results15.11.2019 20:06:00 CETPress release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the third quarter of 2019 on Thursday, November 21, 2019. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Thursday, November 21, 2019 at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will be available from the Investor Relations section of the Company’s website at www.sflcorp.com on the same day. In order to listen to the presentation you may do one of the following: A: Webcast Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast". The webcast with slideshow will be played live from this platform. To listen to the conference call from the website, you need to have installed Windows Media Player, and you need to have a sound card on your computer. B: Conference Call Participants dial-in details: US Toll Free telephone number +1 866 966 1396 International Dial-in te

Cavotec’s Nomination Committee ahead of Annual General Meeting 202015.11.2019 18:00:00 CETPress release

The Nomination Committee of Cavotec SA (“Cavotec”) consists of members appointed by Cavotec’s Board of Directors, in accordance with Cavotec's Internal Regulations. The composition of the members of the Nomination Committee presented below is in line with the recommendations of the Swedish Corporate Governance Code. The main purpose and responsibility of the Nomination Committee is to present proposals for the election and remuneration of the Chairman and the Board of Directors as well as the Auditors to the Annual General Meeting 2020. The Board of Directors has decided that the four largest shareholders and the Chairman of Cavotec’s Board of Directors shall be represented in the Nomination Committee. On 31 October 2019, the four largest shareholders recorded in the company’s share register were Bure Equity AB (27.1% of the vote), AP4 (9.8% of the vote), Nomina SA (8.1% of the vote) and Founding Shareholders (Stefan Widegren, Lars Hellman and Peter Brandel with families) (11.9 % of th

Touax: Nine-Month Revenue From Activities: +4.9%15.11.2019 17:45:00 CETPress release

PRESS RELEASE Paris, 15 November 2019 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION NINE-MONTH REVENUE FROM ACTIVITIES: +4.9% Revenue 1 up 1.4% in the third quarter of 2019, Revenue up 4.9% over the first nine months of the year (+1.5% at constant scope and currency) validating the group’s strategic objectives ANALYSIS OF REVENUE FROM ACTIVITIES Q3 2019 revenue totalled €40.1 million vs. €39.6 million in Q3 2018, an increase of 1.4%. Over the first nine months of the year, revenue from activities totalled €119.6 million (€115.7 million at constant scope and currency), up 4.9% compared to the same period in 2018. Revenue from leasing activities amounted to 99.8 million euros (96.8 million euros at constant scope and currency) at 30 September 2019, including a 10% increase in the Leasing Revenue on owned equipment (36.9 million euros). Leasing Revenue from leasing activities stood at 99.9 million euros in the first nine months of 2018. Sales rose to €19 million (€14.2 million at constant